Friday, June 16, 2017

Guselkumab at the 2017 EULAR Annual Meeting in Madrid

You might never have heard about guselkumab, which targets IL-23. Other MABs targeting IL-23 include briakinumab (nothing at the EULAR 2017 meeting), tildrakizumab (nothing at the EULAR 2017 meeting), and ustekinumab (already available as Stelara). To be more specific: guselkumab (GUS) is a fully human monoclonal antibody (MAB) against the p19 subunit of IL-23.

A. Deodhar and colleagues published [1]: “EFFICACY AND SAFETY RESULTS OF GUSELKUMAB, AN ANTI-IL23 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 24 WEEKS: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY”. The authors concluded: “In pts with active PsA [psoriatic arthritis] and 3% BSA [Body Surface Area] of psoriasis, GUS demonstrated significant improvement on joint symptoms, physical function, psoriasis, enthesitis, dactylitis and quality of life. GUS was well tolerated with no unexpected safety findings in this population.”

It’s still too early to do projections into the future. A word of warning however: we had hardly any options to treat psoriatic arthritis for long time, now we see a proliferation of different principles. Psoriatic arthritis is less common than rheumatoid arthritis; PsA has a prevalence of 0.16-0.25 % and RA 0.5-1.0 % [2]. Though we are happy for any new therapeutic principle, we shall have a long way to put all the options into a working algorithm.

Links and References:
[1] Annals of the Rheumatic Diseases, volume 76, supplement 2, year 2017, page 142 / Session: PsA: the options grow! , (Oral Presentations ) /
DOI: 10.1136/annrheumdis-2017-eular.1164


No comments:

Post a Comment